Compare SID & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | TRVI |
|---|---|---|
| Founded | 1941 | 2011 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2002 | 2019 |
| Metric | SID | TRVI |
|---|---|---|
| Price | $1.17 | $13.60 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $1.40 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 3.6M | 982.4K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.71 | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $5.41 |
| 52 Week High | $2.20 | $16.12 |
| Indicator | SID | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 45.75 |
| Support Level | N/A | $13.12 |
| Resistance Level | $1.43 | $14.57 |
| Average True Range (ATR) | 0.07 | 0.53 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 13.24 | 23.23 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.